Intuitive Surgical, Inc. $ISRG Shares Acquired by Peloton Wealth Strategists

Peloton Wealth Strategists lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 149.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,984 shares of the medical equipment provider’s stock after buying an additional 1,788 shares during the period. Peloton Wealth Strategists’ holdings in Intuitive Surgical were worth $1,690,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Norges Bank purchased a new stake in Intuitive Surgical in the fourth quarter valued at approximately $2,856,987,000. Northwestern Mutual Wealth Management Co. increased its position in Intuitive Surgical by 1,043.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,342,121 shares of the medical equipment provider’s stock worth $760,124,000 after purchasing an additional 1,224,734 shares during the period. Polen Capital Management LLC acquired a new position in Intuitive Surgical during the fourth quarter worth $477,225,000. Assenagon Asset Management S.A. boosted its position in shares of Intuitive Surgical by 106.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,533,771 shares of the medical equipment provider’s stock worth $868,667,000 after purchasing an additional 791,516 shares in the last quarter. Finally, Amundi boosted its position in shares of Intuitive Surgical by 29.7% during the 3rd quarter. Amundi now owns 3,227,472 shares of the medical equipment provider’s stock worth $1,451,362,000 after purchasing an additional 739,444 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Trading Up 0.1%

Shares of ISRG opened at $417.07 on Wednesday. Intuitive Surgical, Inc. has a 12-month low of $396.68 and a 12-month high of $603.88. The stock has a market cap of $147.71 billion, a P/E ratio of 50.55, a PEG ratio of 3.39 and a beta of 1.46. The company has a 50-day moving average of $441.47 and a two-hundred day moving average of $493.43.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, beating the consensus estimate of $2.08 by $0.42. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The company’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.81 earnings per share. As a group, analysts forecast that Intuitive Surgical, Inc. will post 8.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ISRG shares. Citigroup upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 price target for the company in a report on Wednesday, March 11th. Leerink Partners decreased their price objective on shares of Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. UBS Group lowered their target price on shares of Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. TD Cowen dropped their target price on shares of Intuitive Surgical from $660.00 to $585.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Finally, Piper Sandler reissued an “overweight” rating and set a $580.00 price target on shares of Intuitive Surgical in a research note on Tuesday, June 2nd. Nineteen investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $573.42.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Iman Jeddi sold 5,625 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the completion of the transaction, the senior vice president owned 6,463 shares of the company’s stock, valued at approximately $2,718,014.65. This trade represents a 46.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 500 shares of Intuitive Surgical stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $473.46, for a total value of $236,730.00. Following the sale, the director owned 239 shares of the company’s stock, valued at approximately $113,156.94. This represents a 67.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,169 shares of company stock worth $3,059,135 in the last ninety days. Insiders own 0.60% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.